(A) The bar diagram indicates the expression of PD-L1 on peripheral blood
cells and platelets from healthy volunteers or MPN patients.
(B) The histograms show PD-L1 expression on peripheral blood cells and
platelets in healthy individuals or MPN patients as described in (A).
(C) The bar diagrams show PD-L1 expression in different cell types: T cells
(CD3+), B cells (CD19+), monocytes
(CD11b+CD14+), MDSCs
(CD11b+CD33+CD14−), platelets
(CD42b+), and neutrophils
(CD11b+CD15+) from multiple MPN patients and
healthy controls. Data were normalized to the PD-L1 MFI of healthy controls set as 1.
(D, E) The diagrams show PD-L1 expression (MFI) in CD14+
monocytes (D) and CD42b+ platelets (E) from
MPN patients on day 2 before ruxolitinib-treatment and 10 days after start of ruxolitinib.
Each data point indicates the measurement of an individual patient at the indicated time
point. The P value was determined by using the Wilcoxon matched-pairs
signed rank test.
(F) The bar diagram shows the pSTAT3/STAT3/β-actin ratio within
PBMCs from MPN patients on day 2 before ruxolitinib treatment and 10 days after start of
ruxolitinib. Pooled results from 21 patients.
(G) The Western blots show pSTAT3 and STAT3 protein amounts within PBMCs
from 3 representative MPN patients on day 2 before ruxolitinib treatment and 10 days after
start of ruxolitinib.
(H) Displayed are representative BM biopsies from a healthy control and
different MPN patients with verified JAK2V617F mutations.
PD-L1+ cells appear in brown. The scale bar represents 50
μm.
(I) The bar diagram displays the number of PD-L1+ cells
out of 300 cells detected in BM biopsies from healthy volunteers or from multiple patients
with the indicated MPN type. PV: polycythemia vera, ET: essential thrombocythemia, PMF:
primary myelofibrosis.
(J) The bar diagram displays the number of PD-L1+
megakaryocytes versus all PD-L1+ non-megakaryocyte cells detected out
of 300 cells examined in BM biopsies of patients with JAK2-mutant MPN. Data are pooled
from 39 patients.